PALO ALTO, PALO AL, CHINA,--GENCI BIOTECHNOLOGY GROUP (NASDAQ: GRCL) (NASDAQ: GRCL) –A global clinical-stage biopharmaceutical company dedicated to developing efficient and cost-effective cell therapies for cancer treatment, today announced that it will officially open its U.S. Innovation and Research Center in San Diego, California, in the first quarter of 2022.
As a key part of the company's globalization strategy, the company is committed to continuously expanding its business development in the United States, and the opening of the innovation and R&D center will further enhance and enrich the company's R&D capabilities, including: independent drug discovery, preclinical research and translational medicine capabilities, providing strong support for building more patented technology platforms and expanding early product pipelines. After an in-depth investigation across the United States, Gensee Finally decided to locate the Cornerstone Research Center in San Diego to set up an innovative R&D center covering leading laboratories and office areas. At the same time, the company also plans to recruit more talents in the field of biotechnology in the United States and continue to grow the company's research and development team.
"We are delighted to begin 2022 with the official opening of our U.S. Innovation Center, which not only further strengthens the company's R&D capabilities, but also deepens our presence in the U.S.," said Dr. Wei Cao, Founder, Chairman and CEO of Gensy Biotech. "Entering San Diego, the biopharmaceutical powerhouse in the United States, heralds the continued steady progress of Gensy Biotech towards its goal of becoming the world's leading cell therapy company. By continuously developing a series of proprietary platforms and technologies, including FasTCAR and TruUCAR, we are always focused on solving the existing challenges of traditional CAR-T cell therapies, and look forward to translating more differentiated innovations to benefit cancer patients worldwide. ”
About the Creatures of Joy
Gensy Biotechnology Group ("Gensy Biotech") is a global clinical-stage biopharmaceutical company dedicated to the discovery and development of breakthrough cell therapies. Leveraging its groundbreaking three breakthrough technology platforms of FasTCAR, TruUCAR and SMART CARTTM, Gensy is developing a broad pipeline of autologous and allogeneic cancer treatment products at the clinical stage. These products are expected to overcome the major industry challenges that persist with traditional CAR-T therapies, including long production times, poor production quality, high treatment costs, and lack of effective treatment for solid tumors.
![Gensy Biotech announced that the U.S. research institute will be unveiled in Q1 2022[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)